Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07288138 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
MinorTrial sites expanded: 64 → 68 locationsEligibility criteria expanded, about 14 words · Secondary endpoints: details revised at 1 of 35 entriesShow 2 more changesShow less
Eligibility criteria expanded, about 14 words
Secondary endpoints: details revised at 1 of 35 entries
MinorSite details revised at 1 of 64 sitesv13
MinorStudy sites: 63 to 64v12
MinorStudy sites: 62 to 63v11
MinorRe-verified, no change to tracked fieldsv10
MinorTrial sites expanded: 58 → 62 locationsv9
MinorStudy sites: 56 to 58v8
MinorTrial sites expanded: 53 → 56 locationsv7
NotablePrimary completion pushed from Oct 16, 2026 to Sep 15, 2027Trial sites expanded: 39 → 53 locations · Completion pushed from Oct 30, 2026 to Sep 29, 2027 · Eligibility criteria expanded, about 67 words · 1 morev6Show 4 more changesShow less
Trial sites expanded: 39 → 53 locations
Completion pushed from Oct 30, 2026 to Sep 29, 2027
MinorStudy sites: 2 to 13Primary completion date: Jan 2027 to Oct 16, 2026 · Completion date: Jan 2027 to Oct 30, 2026v4Show 2 more changesShow less
Primary completion date: Jan 2027 to Oct 16, 2026
Completion date: Jan 2027 to Oct 30, 2026
MinorStudy sites: 1 to 2v3
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 1v2Show 1 more changeShow less
Study sites: 0 to 1
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.